{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:08:51Z","timestamp":1792058931155,"version":"4.4.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"1","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2024,1,2]]},"DOI":"10.1080\/17460441.2023.2267001","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:59:37Z","timestamp":1697191177000},"page":"9-20","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option"],"prefix":"10.1080","volume":"19","author":[{"given":"Sara","family":"Ferraro","sequence":"first","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7883-3657","authenticated-orcid":false,"given":"Irma","family":"Convertino","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Cappello","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Valdiserra","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bonaso","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8486","authenticated-orcid":false,"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[{"name":"Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa Italy"},{"name":"Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2022.2146493"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c03881"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19662-4"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21475"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00117"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01692-5"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.630500"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.2c01359"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.1c00039"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00509"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-440X(96)80061-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac257"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq4064"},{"key":"e_1_3_4_17_1","first-page":"193","article-title":"A phase 1 study of S-217622 in healthy adult participants [Internet]. International clinical trials Registry Platform","volume":"30","author":"Tsutae N","year":"2021","unstructured":"Tsutae N. A phase 1 study of S-217622 in healthy adult participants [Internet]. International clinical trials Registry Platform. World Health Org. 2021 [cited 2023 Apr 26];30:193\u2013209. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031210202","journal-title":"World Health Org"},{"key":"e_1_3_4_18_1","unstructured":"Shionogi. A phase 3 Multicenter randomized double-blind 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 [Internet]. ClinicalTrial.Gov. 2022 [cited 2023 Apr 26]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT05305547"},{"key":"e_1_3_4_19_1","unstructured":"University of Oxford. Finding treatments for COVID-19: a phase 2 multi-centre adaptive Platform trial to assess antiviral pharmacodynamics in Early symptomatic COVID-19 (PLATCOV) [Internet]. ClinicalTrial.Gov. 2021 [cited 2023 Apr 26]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT05041907"},{"key":"e_1_3_4_20_1","unstructured":"Portsmouth S A phase 3 multicenter randomized double-blind 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 - SCORPIO-HR [Internet]. International Clinical Trials Registry Platform World Health Organization. 2022 [cited 2023 Apr 26]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031220353"},{"key":"e_1_3_4_21_1","unstructured":"ICTRP Search Portal (JPRN-jRCT2031210350) [Internet]. International clinical trials Registry Platform World Health Organization. 2021 [cited 2023 Apr 26]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031210350"},{"key":"e_1_3_4_22_1","article-title":"Drug-drug interaction study of S-217622 in healthy adult participants [Internet]. International clinical trials Registry Platform","author":"Tsutae N","year":"2022","unstructured":"Tsutae N. Drug-drug interaction study of S-217622 in healthy adult participants [Internet]. International clinical trials Registry Platform. World Health Org. 2022 [cited 2023 Apr 26]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031210595","journal-title":"World Health Org"},{"key":"e_1_3_4_23_1","unstructured":"Seoul National University Bundang Hospital. A multicenter adaptive randomised controlled trial Platform to evaluated safety and Efficacy of strategies and treatments for hospitalized patients with respiratory infections [Internet]. International Clinical Trials Registry Platform World Health Organization. 2023 [[cited 2023 Apr 26]]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=KCT0008328"},{"key":"e_1_3_4_24_1","article-title":"A phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 [Internet]","author":"Shionogi","year":"2022","unstructured":"Shionogi. A phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 [Internet]. International Clinical Trials Registry Platform, World Health Organization. 2022 [cited 2023 Apr 26]. Identifier: PACTR202303499747084. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=PACTR202303499747084","journal-title":"International Clinical Trials Registry Platform, World Health Organization"},{"key":"e_1_3_4_25_1","article-title":"A phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 [Internet]","author":"Kishimoto C","year":"2023","unstructured":"Kishimoto C. A phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 [Internet]. International Clinical Trials Registry Platform, World Health Organization. 2023 [cited 2023 Apr 26]. Identifier: CTRI\/2023\/01\/048757. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2023\/01\/048757","journal-title":"International Clinical Trials Registry Platform, World Health Organization"},{"key":"e_1_3_4_26_1","unstructured":"Univeristy of Minnesota. Strategies and Treatments for respiratory infections & Am; viral emergencies (STRIVE): Shionogi protease inhibitor [Internet]. ClinicalTrial.Gov. 2022 [cited 2023 Apr 26]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NCT05605093"},{"key":"e_1_3_4_27_1","unstructured":"ICTRP Search Portal [Internet]. [cited 2023 Apr 18]. Available from: https:\/\/trialsearch.who.int\/"},{"key":"e_1_3_4_28_1","unstructured":"Medicine USNUSNL of M of. Search of: S-217622 or ensitrelvir | COVID-19 - list results - ClinicalTrials.Gov [Internet]. Clinicaltrial.Gov Database. 2023 [cited 2023 Apr 26]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=COVID-19&term=S-217622+OR+ensitrelvir&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&l"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00632-22"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2247"},{"key":"e_1_3_4_31_1","unstructured":"Shionogi. Shionogi filed for emergency use authorization of ensitrelvir fumaric acid in Taiwan for the treatment of COVID-19\uff5cShionogi & co. Ltd. [Internet]. Shionogi Website. 2023 [cited 2023 Apr 17]. Available from: https:\/\/www.shionogi.com\/global\/en\/news\/2023\/04\/20230411.html"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac933"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00697-22"},{"issue":"8","key":"e_1_3_4_34_1","first-page":"E33024","article-title":"A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (phase 3 part)","volume":"102","author":"Yotsuyanagi H","year":"2023","unstructured":"Yotsuyanagi H, Ohmagari N, Doi Y, et al. A phase 2\/3 study of S-217622 in participants with SARS-CoV-2 infection (phase 3 part). Med (United States). 2023 Feb 22[cited 2023 Apr 27];102(8):E33024. Available from. https:\/\/journals.lww.com\/md-journal\/Fulltext\/2023\/02220\/A_phase_2_3_study_of_S_217622_in_participants_with.7.aspx.Medicine","journal-title":"Med (United States)"},{"key":"e_1_3_4_35_1","unstructured":"Shionogi. Shionogi & co. Ltd. Announces two Late-Breaking Poster Presentations Featuring New results from the phase 3 and phase 2B\/3 parts of the pivotal SCORPIO-SR trial | MarketScreener [Internet]. MarketScreener Website. 2023 [cited 2023 Apr 28]. Available from: https:\/\/www.marketscreener.com\/quote\/stock\/SHIONOGI-CO-LTD-6493659\/news\/Shionogi-Co-Ltd-Announces-Two-Late-Breaking-Poster-Presentations-Featuring-New-Results-from-the-43432229\/"},{"key":"e_1_3_4_36_1","unstructured":"Shionogi. Shionogi presents pivotal ensitrelvir fumaric acid phase 3 data and exploratory long COVID data at CROI\uff5cShionogi & co. Ltd. [Internet]. Shionogi Website. 2023 [cited 2023 Apr 28]. Available from: https:\/\/www.shionogi.com\/global\/en\/news\/2023\/02\/20230222.html"},{"key":"e_1_3_4_37_1","unstructured":"Uehara T Yotsuyanagi H Ohmagari N et al. Ensitrelvir for mild-to-moderate COVID-19: phase 3 part of phase 2\/3 study [Internet]. Shionogi Website. [cited 2023 Apr 28]. Available from: https:\/\/www.shionogi.com\/content\/dam\/shionogi\/global\/investors\/ir-library\/presentation\/2022\/CROI20230222.pdf"},{"key":"e_1_3_4_38_1","unstructured":"Shionogi. Shionogi Advances ensitrelvir Fumaric Acid COVID-19 antiviral clinical Program \uff5cShionogi & co. Ltd. [Internet]. Shionogi Website. 2023 [cited 2023 Apr 28]. Available from: https:\/\/www-shionogi-com.translate.goog\/global\/en\/news\/2023\/02\/20230215.html?_x_tr_sl=en&_x_tr_tl=it&_x_tr_hl=it&_x_tr_pto=sc"},{"key":"e_1_3_4_39_1","unstructured":"Shionogi. ECCMID 2023: Shionogi to present data showing COVID-19 symptom recurrence is not associated with ensitrelvir treatment. additional data to be presented showing significantly faster time to negative viral titer (culture) compared to placebo\uff5cShionogi & co. [Internet]. Shionogi Website. 2023 [cited 2023 Apr 28]. Available from: https:\/\/www.shionogi.com\/global\/en\/news\/2023\/04\/20230405.html"},{"key":"e_1_3_4_40_1","unstructured":"Ministry of Health L and W. Report On The Deliberation Results [Internet]. 2022 [cited 2023 Apr 17]. Available from: https:\/\/www.pmda.go.jp\/files\/000249828.pdf"},{"key":"e_1_3_4_41_1","unstructured":"Shionogi. Shionogi receives U.S. FDA fast track designation for ensitrelvir fumaric acid an investigational oral antiviral for COVID-19\uff5cShionogi & co. Ltd. [Internet]. Shionogi Website. 2023 [cited 2023 Apr 17]. Available from: https:\/\/www.shionogi.com\/global\/en\/news\/2023\/04\/20230404.html"},{"key":"e_1_3_4_42_1","unstructured":"ClinicalTrials.gov [Internet]. [cited 2023 Apr 18]. Available from: https:\/\/beta.clinicaltrials.gov\/search?distance=50&term=ensitrelvir"},{"key":"e_1_3_4_43_1","unstructured":"VigiAccess [Internet]. [cited 2023 Apr 28]. Available from: https:\/\/www.vigiaccess.org\/"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104559"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05514-2"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s44259-023-00009-0"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade8778"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.3c00538"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1960819"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2022.2058486"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00311-5"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2023.2170348"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3290(06)60296-3"},{"key":"e_1_3_4_54_1","unstructured":"Shionogi. Research topics | drug discovery | Shionogi & co. Ltd [Internet]. Shionogi website. [cited 2023 Sep 6]. Available from: https:\/\/www.shionogi.com\/global\/en\/innovation\/randd\/drug-discovery\/our-strength-and-new-modality.html"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1109632"},{"key":"e_1_3_4_56_1","unstructured":"[no author listed]. Shionogi enrolls the first participant in Japan in its global phase 3 trial of ensitrelvir for the prevention of symptomatic [Internet]. Bloomberg Website. 2023 [cited 2023 Jun 30]. Available from: https:\/\/www.bloomberg.com\/press-releases\/2023-06-09\/shionogi-enrolls-the-first-participant-in-japan-in-its-global-phase-3-trial-of-ensitrelvir-for-the-prevention-of-symptomatic"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2023.2267001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T01:24:04Z","timestamp":1727227444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2023.2267001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"alternative-id":["10.1080\/17460441.2023.2267001"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2023.2267001","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}